一种新的肥胖症治疗方法不再以神经元为靶点，而是针对大脑中的支持细胞，从而在不引起恶心的情况下实现减重和更好的血糖控制。人体试验有望在几年内开始。 目前市场上的减肥和糖尿病药物通常无法帮助患者实现长期减重。胰高血糖素样肽-1（Glucagon-like ...

三项最新研究表明，胰高血糖素样肽-1（Glucagon-like peptide-1, GLP-1）药物，如 Ozempic（奥земпик），可能显著降低中风死亡率，改善脑损伤后的恢复，并可能降低整体中风风险。 在神经介入手术学会（Society of NeuroInterventional Surgery, SNIS）第22届年会上，最近展示了三项研究，探讨了使用 GLP-1 抑制剂是否可以减 ...

Serena Williams wants to be transparent and is opening up about her fitness journey, revealing she's taking a GLP-1 ...

A multicenter French study led by Rennes University Hospital reports potential benefits of glucagon-like peptide-1 receptor ...

Some studies have reported reduced secretion of glucagon-like peptide-1 (GLP-1) in patients with type 2 diabetes mellitus; however, other studies have failed to find such an association. The ...

The metabolism of GLP-1 in the body is extremely rapid and the peptide gets inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4), even before leaving the gut. 3 Glucagon is a key hormone in ...

Glucagon-like peptide-1 receptor (GLP-1R) agonists, originally developed for type 2 diabetes patients and popularized by their ability to rapidly reduce body weight in patients with obesity, have ...

The glucagon-like peptide 1 market size has grown strongly in recent years. It will grow from $20.88 billion in 2024 to $22.37 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%.

Novel Glucagon like peptide-1 (GLP-1) drugs were designed and industrial prepared by researchers from Hefei Institutes of Physical Science, Chinese Academy of Sciences Through molecular design ...